SG11201900171QA - Antibody for anti-claudin 18a2 and use thereof - Google Patents
Antibody for anti-claudin 18a2 and use thereofInfo
- Publication number
- SG11201900171QA SG11201900171QA SG11201900171QA SG11201900171QA SG11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA SG 11201900171Q A SG11201900171Q A SG 11201900171QA
- Authority
- SG
- Singapore
- Prior art keywords
- claudin
- antibody
- methods
- immune effector
- present
- Prior art date
Links
- 102000002029 Claudin Human genes 0.000 abstract 1
- 108050009302 Claudin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Abstract
Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours. Fig. 3
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610536449 | 2016-07-08 | ||
PCT/CN2017/082024 WO2017186121A1 (en) | 2016-04-26 | 2017-04-26 | Method for improving function of immune response cell |
PCT/CN2017/092381 WO2018006882A1 (en) | 2016-07-08 | 2017-07-10 | Antibody for anti-claudin 18a2 and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900171QA true SG11201900171QA (en) | 2019-02-27 |
Family
ID=60912336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900171QA SG11201900171QA (en) | 2016-07-08 | 2017-07-10 | Antibody for anti-claudin 18a2 and use thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US11111295B2 (en) |
EP (1) | EP3483182A4 (en) |
JP (1) | JP2019531084A (en) |
KR (1) | KR20190038564A (en) |
CN (1) | CN109790222B (en) |
AU (1) | AU2017294276A1 (en) |
BR (1) | BR112019000327A8 (en) |
CA (1) | CA3030257A1 (en) |
CL (1) | CL2019000061A1 (en) |
IL (1) | IL264144B2 (en) |
SG (1) | SG11201900171QA (en) |
WO (1) | WO2018006882A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019000327A8 (en) * | 2016-07-08 | 2022-10-18 | Carsgen Therapeutics Co Ltd | ANTICLAUDIN 18A2 ANTIBODY AND USE THEREOF |
KR20200143672A (en) | 2018-02-02 | 2020-12-24 | 카르스젠 테라퓨틱스 컴퍼니, 리미티드 | Combination of cellular immunotherapy |
KR20200129116A (en) | 2018-03-08 | 2020-11-17 | 페인스 테라퓨틱스 인코포레이티드 | Anti-Claudin 18.2 Antibodies and Uses thereof |
US20220110973A1 (en) * | 2018-03-09 | 2022-04-14 | Cafa Therapeutics Limited | Method and composition for treating tumors |
RU2020128013A (en) * | 2018-03-14 | 2022-04-15 | Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. | ANTIBODIES AGAINST CLAUDIN 18.2 |
WO2019210863A1 (en) | 2018-05-03 | 2019-11-07 | 科济生物医药(上海)有限公司 | Immune effector cell and use thereof |
CA3100446A1 (en) | 2018-05-15 | 2019-11-21 | Carsgen Therapeutics Co., Ltd. | Genetically engineered cell and application thereof |
SG10202111141WA (en) * | 2018-05-18 | 2021-11-29 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
US20210292427A1 (en) | 2018-07-24 | 2021-09-23 | Cafa Therapeutics Limited | Method for treating tumor using immune effector cell |
US20210214433A1 (en) * | 2018-07-25 | 2021-07-15 | Accurus Biosciences, Inc. | Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof |
CN110857322A (en) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | Anti-human claudin18.2 monoclonal antibody and application thereof |
KR20210050547A (en) * | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | Anti-Claudin18.2 Antibodies and Uses thereof |
CN109206524B (en) * | 2018-09-25 | 2022-04-05 | 山东兴瑞生物科技有限公司 | anti-Claudin 18A2 chimeric antigen receptor, T cell modified by same, and preparation method and application of T cell |
JP2022511394A (en) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Combination therapy of CLDN18 antibody and chemotherapeutic drug |
BR112021011014A2 (en) * | 2018-12-07 | 2021-08-31 | Zlip Holding Limited | ANTI-CLAUDINE ANTIBODIES AND USES THEREOF |
CN113164408A (en) | 2018-12-07 | 2021-07-23 | 科济生物医药(上海)有限公司 | Tumor combined immunotherapy |
CN113166246A (en) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | Antibody and application thereof |
US20220073643A1 (en) * | 2018-12-28 | 2022-03-10 | Nanjing GenScript Biotech Co., Ltd. | Claudin18.2 binding moieties and uses thereof |
EP3909590A4 (en) | 2019-01-07 | 2022-11-16 | CRAGE medical Co., Limited | Cellular immunotherapy combination |
CN116333141A (en) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | anti-CLD 18A2 nano antibody and application thereof |
CN109762067B (en) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
KR20210134321A (en) * | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | Anti-claudin 18 antibodies and methods of use thereof |
CN113490689A (en) * | 2019-02-01 | 2021-10-08 | 佧珐药业有限公司 | TCR fusion proteins and cells expressing TCR fusion proteins |
WO2020198413A1 (en) * | 2019-03-27 | 2020-10-01 | The Trustees Of The University Of Pennsylvania | Tn-muc1 chimeric antigen receptor (car) t cell therapy |
KR20210144792A (en) * | 2019-03-29 | 2021-11-30 | 페인스 테라퓨틱스 인코포레이티드 | Humanized Anti-Claudin 18.2 Chimeric Antigen Receptor and Uses Thereof |
KR20210148216A (en) * | 2019-04-01 | 2021-12-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Anti-claudin 18.2 antibody and its applications |
JP2022529703A (en) * | 2019-04-19 | 2022-06-23 | 康▲諾▼▲亞▼生物医葯科技(成都)有限公司 | Tumor therapeutic agents and their applications |
CN111978402B (en) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | Novel CLDN18.2 binding molecules |
CA3141504A1 (en) * | 2019-05-24 | 2020-12-03 | Sanyou Biopharmaceuticals Co., Ltd. | Novel cldn18.2 binding molecule |
EP3929214A4 (en) * | 2019-05-30 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | Antibody or chimeric antigen receptor which targets claudin 18.2 |
CN114364701A (en) * | 2019-07-17 | 2022-04-15 | 加利福尼亚大学董事会 | Encapsulated protein 18 antibodies and methods of treating cancer |
CN112574307B (en) | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | Anti-human Claudin18.2 antibody and application thereof |
BR112022008653A2 (en) * | 2019-11-05 | 2022-07-19 | Lanova Medicines Ltd | ANTIBODY-DRUG CONJUGATE, METHOD TO TREAT CANCER, AND, USE OF ANTIBODY-DRUG CONJUGATE |
WO2021104511A1 (en) * | 2019-11-29 | 2021-06-03 | 苏州诺沃泰医药科技有限公司 | Application of car t-cells in preparing drug for treating cancer |
KR20220111308A (en) | 2019-12-06 | 2022-08-09 | 소티오 바이오테크 에이.에스. | Humanized CLDN18.2 Antibody |
CN114901365A (en) | 2019-12-23 | 2022-08-12 | 斯迪安生物技术公司 | Tumor specific claudin 18.2 antibody |
CN113272332B (en) * | 2020-01-03 | 2022-11-18 | 上海恺兴诊断技术有限公司 | anti-Claudin18.2 antibody and application thereof |
CA3167349A1 (en) * | 2020-02-10 | 2021-08-19 | Qing Zhou | Claudin 18.2 antibody and use thereof |
WO2021173307A1 (en) * | 2020-02-25 | 2021-09-02 | Gensun Biopharma Inc. | Trispecific t cell engagers |
MX2022014332A (en) * | 2020-05-15 | 2022-12-13 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Antibody drug conjugate, preparation method therefor and use thereof. |
CN111961135B (en) * | 2020-07-13 | 2022-08-16 | 北京亦庄国际蛋白药物技术有限公司 | Antibody for preventing or treating cancer |
CN113929780A (en) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | Humanized antibody for treating cancer by combining claudin |
CN111704669B (en) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | anti-CLDN 18 fully humanized antibody for treating advanced gastric cancer |
WO2022011531A1 (en) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | Anti-cld18a2 single-domain antibody |
WO2022028623A1 (en) | 2020-08-07 | 2022-02-10 | 佧珐药业有限公司 | Engineered cells and method for engineering cells |
CN116390953A (en) * | 2020-09-30 | 2023-07-04 | 南京金斯瑞生物科技有限公司 | Antibodies targeting human claudin 18.2 and uses thereof |
WO2022122709A1 (en) * | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
US20220227832A1 (en) | 2020-12-21 | 2022-07-21 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
WO2022214089A1 (en) | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | Cellular immunotherapy use |
CN117480247A (en) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | Chimeric T cell receptor and uses thereof |
WO2023274303A1 (en) | 2021-06-29 | 2023-01-05 | 科济生物医药(上海)有限公司 | Chimeric polypeptide for regulating cell physiological activity |
CN113788894B (en) * | 2021-09-03 | 2022-08-05 | 深圳市先康达生命科学有限公司 | Monoclonal antibody targeting human Claudin18.2 protein and application thereof |
WO2023078386A1 (en) * | 2021-11-05 | 2023-05-11 | 正大天晴药业集团股份有限公司 | Anti-cldn18.2 antibody and use thereof |
WO2023213280A1 (en) * | 2022-05-06 | 2023-11-09 | 上海先博生物科技有限公司 | Chimeric antigen t cell receptor targeting cldn18.2 and use thereof |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
CN117430708B (en) * | 2023-12-21 | 2024-04-09 | 苏州近岸蛋白质科技股份有限公司 | anti-Claudin18.2 antibody |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
CN112979828A (en) * | 2014-07-17 | 2021-06-18 | 恺兴生命科技(上海)有限公司 | T lymphocyte targeting CLD18A2 and preparation method and application thereof |
CN105331585A (en) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent |
RU2018124319A (en) | 2015-12-04 | 2020-01-09 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | NEW ANTIBODIES TO CLAUDIN AND WAYS OF THEIR APPLICATION |
WO2017186121A1 (en) * | 2016-04-26 | 2017-11-02 | 科济生物医药(上海)有限公司 | Method for improving function of immune response cell |
BR112019000327A8 (en) * | 2016-07-08 | 2022-10-18 | Carsgen Therapeutics Co Ltd | ANTICLAUDIN 18A2 ANTIBODY AND USE THEREOF |
US20220110973A1 (en) * | 2018-03-09 | 2022-04-14 | Cafa Therapeutics Limited | Method and composition for treating tumors |
JP2022511394A (en) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Combination therapy of CLDN18 antibody and chemotherapeutic drug |
EP3909590A4 (en) * | 2019-01-07 | 2022-11-16 | CRAGE medical Co., Limited | Cellular immunotherapy combination |
US20230272341A1 (en) * | 2020-08-10 | 2023-08-31 | Crage Medical Co., Limited | Multifunctional immune effector cell and use thereof |
-
2017
- 2017-07-10 BR BR112019000327A patent/BR112019000327A8/en unknown
- 2017-07-10 JP JP2019521178A patent/JP2019531084A/en active Pending
- 2017-07-10 SG SG11201900171QA patent/SG11201900171QA/en unknown
- 2017-07-10 CN CN201780042611.4A patent/CN109790222B/en active Active
- 2017-07-10 IL IL264144A patent/IL264144B2/en unknown
- 2017-07-10 WO PCT/CN2017/092381 patent/WO2018006882A1/en unknown
- 2017-07-10 KR KR1020197003874A patent/KR20190038564A/en not_active Application Discontinuation
- 2017-07-10 AU AU2017294276A patent/AU2017294276A1/en active Pending
- 2017-07-10 US US16/316,331 patent/US11111295B2/en active Active
- 2017-07-10 EP EP17823694.9A patent/EP3483182A4/en active Pending
- 2017-07-10 CA CA3030257A patent/CA3030257A1/en active Pending
-
2019
- 2019-01-08 CL CL2019000061A patent/CL2019000061A1/en unknown
-
2021
- 2021-08-05 US US17/395,223 patent/US20220185880A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019531084A (en) | 2019-10-31 |
CN109790222A (en) | 2019-05-21 |
US11111295B2 (en) | 2021-09-07 |
RU2019101430A (en) | 2020-08-10 |
CN109790222B (en) | 2022-03-15 |
US20220185880A1 (en) | 2022-06-16 |
WO2018006882A1 (en) | 2018-01-11 |
CL2019000061A1 (en) | 2019-05-03 |
BR112019000327A8 (en) | 2022-10-18 |
IL264144B2 (en) | 2023-11-01 |
IL264144A (en) | 2019-02-28 |
EP3483182A4 (en) | 2020-07-29 |
US20190233511A1 (en) | 2019-08-01 |
IL264144B1 (en) | 2023-07-01 |
RU2019101430A3 (en) | 2021-05-17 |
CA3030257A1 (en) | 2018-01-11 |
KR20190038564A (en) | 2019-04-08 |
EP3483182A1 (en) | 2019-05-15 |
BR112019000327A2 (en) | 2019-08-13 |
AU2017294276A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900171QA (en) | Antibody for anti-claudin 18a2 and use thereof | |
PH12019500193A1 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
MY191169A (en) | Anti-fcrh5 antibodies | |
WO2017134302A3 (en) | Targeted therapeutic agents and uses thereof | |
SG11201906780SA (en) | Bcma-targeting antibody and use thereof | |
MY194032A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
SG10201804931QA (en) | Anti-cll-1 antibodies and immunoconjugates | |
PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
MY186334A (en) | Anti-her2 antibodies and immunoconjugates | |
EP3964527A3 (en) | Combination therapy for cancer | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2021013837A (en) | Combination immunotherapy approach for treatment of cancer. | |
MX2019007020A (en) | Il-11 antibodies. | |
BR112018003339A2 (en) | fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
SG10201901707QA (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
MX2019007021A (en) | Il-11ra antibodies. | |
MY191581A (en) | Anti-pd-1 antibodies | |
MX2020011783A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer. | |
SG10201806108TA (en) | Binding proteins and methods of use thereof | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
MX2021006681A (en) | Anti-claudin antibodies and uses thereof. | |
WO2017139570A8 (en) | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine |